TLN-121 / Treeline Biosci - LARVOL DELTA

Treeline, Roche Partner on TLN-121 Lymphoma Trial (Contract Pharma) - "The Phase 1 study will evaluate the combinations in separate cohorts, including patients with diffuse large B-cell lymphoma (DLBCL), a common and aggressive form of B-cell lymphoma...Treeline will sponsor and conduct the Phase 1 dose-escalation and expansion study, while Roche will provide glofitamab and mosunetuzumab for specified expansion cohorts. Treeline expects to begin combination dosing in those cohorts in the fourth quarter of 2026."

Licensing / partnership • Diffuse Large B Cell Lymphoma

Treeline Announces First Clinical Trials and Secures $200M in Additional Funding (Businesswire) - "Treeline Biosciences (or Treeline) today announced the initiation of Phase 1 trials for two internally discovered programs, TLN-121 and TLN-372, and a third in-licensed program, TLN-254."

Financing • Trial status • Lymphoma • Solid Tumor

TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas (clinicaltrials.gov) - P1 | N=180 | Recruiting | Sponsor: Treeline Biosciences, Inc.

New P1 trial • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology